FDA Approves AMITIZA, Chronic Idiopathic Constipation Agent - Sucampo and Takeda Pharmaceuticals to Begin Joint Promotion in Spring.Tokyo, Japan, Feb 1, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Pharmaceutical announced on February 1 that its US sales partner Sucampo Pharmaceuticals have obtained approval for AMITIZA capsules (lubiprostone), an oral treatment of chronic idiopathic constipation in adults, from the US Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ). AMITIZA, which is discovered by Sucampo Pharmaceuticals, is the world's first selective chloride channel Chloride channels are a superfamily of poorly understood ion channels consisting of approximately 13 members. It is now recognised that chloride channels display a variety of important physiological and cellular roles that include regulation of pH, volume homeostasis, activator indicated for treating chronic idiopathic constipation. Going forward, Sucampo Pharmaceutiacls, Takeda Pharmaceuticals North America North America, third largest continent (1990 est. pop. 365,000,000), c.9,400,000 sq mi (24,346,000 sq km), the northern of the two continents of the Western Hemisphere. and Takeda Pharmaceuticals America will be jointly marketing AMITIZA. The new agent will be available in the US in spring 2006. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion